title: Immunosuppressive drugs inhibit the production of interleukin-6 and interleukin-8 in cultured cardiac myxoma cells.
abstract: Cardiac myxoma cells produce large amounts of interleukin (IL)-6 and IL-8. To determine whether immunosuppressive agents could be used to treat cardiac myxoma, we tested the effects of dexamethasone and three of the newer second-generation immunosuppressive drugs, cyclosporin A, tacrolimus, and deoxyspergualin, on the production of IL-6 and IL-8 in these cells. Cultured cardiac myxoma cells were used as in vitro model of cardiac myxoma. Cells were tested for 24 hours with 10(-7) M dexamethasone, 10(-6) M cyclosporin A, 10(-8) M tacrolimus, and 10(-6) M 15-deoxyspergualin, with aliquots of conditioned medium being assayed for cytokine levels at 0, 6, 12, and 24 hours. Cardiac myxoma cells isolated from 4 patients all produced quantities of IL-6 and IL-8. The concentrations of IL-6 in the medium after 7 days in culture ranged from 79,000 to 2,740,000 pg/ml, and the concentrations of IL-8 ranged from 40,000 to 1,000,000 pg/ml. Exposure of cyclosporin A and dexamethasone almost completely inhibited the production of IL-6 and IL-8 after 24 hours of treatment. Tacrolimus inhibited the production of both cytokines by 55%, while 15-deoxyspergualin reduced IL-6 levels by 24% and IL-8 levels by 48% after separate 24 hour treatments. These results suggest that these newer immunosuppressive agents may be useful in reducing the production of IL-6 and IL-8 in patients with cardiac myxoma.
authors.affiliation: Second Department of Internal Medicine, Gunma University School of Medicine, Japan. sakamoth@news.sb.gunma-u.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Sakamoto
authors.forename: T
authors.initials: T
authors.lastname: Sakamaki
authors.forename: T
authors.initials: T
authors.lastname: Kanda
authors.forename: Y
authors.initials: Y
authors.lastname: Hirao
authors.forename: Y
authors.initials: Y
authors.lastname: Ohyama
authors.forename: K
authors.initials: K
authors.lastname: Ogishi
authors.forename: M
authors.initials: M
authors.lastname: Negishi
authors.forename: H
authors.initials: H
authors.lastname: Masuda
authors.forename: H
authors.initials: H
authors.lastname: Sumino
authors.forename: Y
authors.initials: Y
authors.lastname: Sawada
authors.forename: Z
authors.initials: Z
authors.lastname: Ono
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: R
authors.initials: R
authors.lastname: Nagai
mesh_terms: D000368:Aged; D005260:Female; D006338:Heart Neoplasms / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D015850:Interleukin-6 / Q000096:biosynthesis / Q000378:metabolism; D016209:Interleukin-8 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009232:Myxoma / Q000378:metabolism* / Q000473:pathology; D014407:Tumor Cells, Cultured; D000093242:Interleukin-6 Inhibitors
chemical_list: D007166:Immunosuppressive Agents; D015850:Interleukin-6; D016209:Interleukin-8; D000093242:Interleukin-6 Inhibitors